Tang, M. et al. Pulmonary hypertension, mortality, and cardiovascular disease in CKD and ESRD patients: a systematic review and meta-analysis. Am. J. Kidney Dis. 72, 75–83 (2018).
Bolignano, D., Pisano, A., Coppolino, G., Tripepi, G. L. & D’Arrigo, G. Pulmonary hypertension predicts adverse outcomes in renal patients: a systematic review and meta-analysis. Ther. Apher. Dial. 23, 369–384 (2019).
Edmonston, D. L. et al. Pulmonary hypertension subtypes and mortality in CKD. Am. J. Kidney Dis. 75, 713–724 (2020).
Pabst, S. et al. Pulmonary hypertension in patients with chronic kidney disease on dialysis and without dialysis: results of the PEPPER-study. PLoS One 7, e35310 (2012).
Navaneethan, S. D. et al. Presence and outcomes of kidney disease in patients with pulmonary hypertension. Clin. J. Am. Soc. Nephrol. 9, 855–863 (2014).
O’Leary, J. M. et al. Pulmonary hypertension in patients with chronic kidney disease: invasive hemodynamic etiology and outcomes. Pulm. Circ. 7, 674–683 (2017).
Wolfe, J. D. et al. Pulmonary vascular resistance determines mortality in end-stage renal disease patients with pulmonary hypertension. Clin. Transplant. 32, e13270 (2018).
Brinza, C. et al. Pulmonary arterial hypertension and adverse outcomes after kidney transplantation: a systematic review and meta-analysis. J. Clin. Med. 11, 1944 (2022).
Chakinala, M. M. et al. Impact of declining renal function on outcomes in pulmonary arterial hypertension: a REVEAL registry analysis. J. Heart Lung Transplant. 37, 696–705 (2018).
Shah, S. J. et al. Association of serum creatinine with abnormal hemodynamics and mortality in pulmonary arterial hypertension. Circulation 117, 2475–2483 (2008).
Nickel, N. P. et al. Low-grade albuminuria in pulmonary arterial hypertension. Pulm. Circ. 9, 2045894018824564 (2019).
Benza, R. L. et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 122, 164–172 (2010).
Leopold, J. A. et al. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat. Med. 13, 189–197 (2007).
Cohn, J. N. & Tognoni, G. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med. 345, 1667–1675 (2001).
Velazquez, E. J. et al. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N. Engl. J. Med. 380, 539–548 (2019).
Maron, B. A. et al. Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension. Circulation 126, 963–974 (2012).
Maron, B. A. & Leopold, J. A. The role of the renin-angiotensin-aldosterone system in the pathobiology of pulmonary arterial hypertension (2013 Grover Conference series). Pulm. Circ. 4, 200–210 (2014).
Maron, B. A. et al. Plasma aldosterone levels are elevated in patients with pulmonary arterial hypertension in the absence of left ventricular heart failure: a pilot study. Eur. J. Heart Fail. 15, 277–283 (2013).
Zhang, J. et al. Treatment effects of pulmonary artery denervation for pulmonary arterial hypertension stratified by REVEAL risk score: results from PADN-CFDA trial. J. Heart Lung Transplant. 42, 1140-1151 (2023).
Calvier, L. et al. Galectin-3 and aldosterone as potential tandem biomarkers in pulmonary arterial hypertension. Heart 102, 390–396 (2016).
Humbert, M. et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Respir. J. 61, 2200879 (2023).
Leber, L., Beaudet, A. & Muller, A. Epidemiology of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: identification of the most accurate estimates from a systematic literature review. Pulm. Circ. 11, 2045894020977300 (2021).
Maron, B. A. & Galie, N. Diagnosis, treatment, and clinical management of pulmonary arterial hypertension in the contemporary era: a review. JAMA Cardiol. 1, 1056–1065 (2016).
Stevens, P. E., Levin, A. & Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann. Intern. Med. 158, 825–830 (2013).
Ronco, C., Bellasi, A. & Di Lullo, L. Cardiorenal syndrome: an overview. Adv. Chronic Kidney Dis. 25, 382–390 (2018).
Ronco, C., Haapio, M., House, A. A., Anavekar, N. & Bellomo, R. Cardiorenal syndrome. J. Am. Coll. Cardiol. 52, 1527–1539 (2008).
Hoeper, M. M. et al. A global view of pulmonary hypertension. Lancet Respir. Med. 4, 306–322 (2016).
GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 395, 709–733 (2020).
Wang, L. et al. Prognostic effect of pulmonary hypertension in patients with chronic kidney disease: univariate and multivariate analyses of factors associated with survival. Front. Med. 9, 972937 (2022).
Yang, Q. M. & Bao, X. R. Pulmonary hypertension in patients with stage 1–3 chronic kidney disease. Genet. Mol. Res. 13, 5695–5703 (2014).
Verbrugge, F. H., Guazzi, M., Testani, J. M. & Borlaug, B. A. Altered hemodynamics and end-organ damage in heart failure: impact on the lung and kidney. Circulation 142, 998–1012 (2020).
Bitker, L. et al. Presence of kidney disease as an outcome predictor in patients with pulmonary arterial hypertension. Am. J. Nephrol. 47, 134–143 (2018).
Nickel, N. P. et al. Kidney dysfunction in patients with pulmonary arterial hypertension. Pulm. Circ. 7, 38–54 (2017).
Rossi, G. P., Cavallin, M., Nussdorfer, G. G. & Pessina, A. C. The endothelin-aldosterone axis and cardiovascular diseases. J. Cardiovasc. Pharmacol. 38, 49 (2001).
Kopitko, C., Gondos, T., Fulop, T. & Medve, L. Reinterpreting renal hemodynamics: the importance of venous congestion and effective organ perfusion in acute kidney injury. Am. J. Med. Sci. 359, 193–205 (2020).
Mullens, W., Verbrugge, F. H., Nijst, P. & Tang, W. H. W. Renal sodium avidity in heart failure: from pathophysiology to treatment strategies. Eur. Heart J. 38, 1872–1882 (2017).
Selektor, Y. & Weber, K. T. The salt-avid state of congestive heart failure revisited. Am. J. Med. Sci. 335, 209–218 (2008).
Testani, J. M. & Damman, K. Venous congestion and renal function in heart failure … it’s complicated. Eur. J. Heart Fail. 15, 599–601 (2013).
Dilley, J. R., Corradi, A. & Arendshorst, W. J. Glomerular ultrafiltration dynamics during increased renal venous pressure. Am. J. Physiol. 244, 650 (1983).
Braam, B., Cupples, W. A., Joles, J. A. & Gaillard, C. Systemic arterial and venous determinants of renal hemodynamics in congestive heart failure. Heart Fail. Rev. 17, 161–175 (2012).
Mullens, W. et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J. Am. Coll. Cardiol. 53, 589–596 (2009).
Uthoff, H. et al. Central venous pressure and impaired renal function in patients with acute heart failure. Eur. J. Heart Fail. 13, 432–439 (2011).
Gambardella, I. et al. Congestive kidney failure in cardiac surgery: the relationship between central venous pressure and acute kidney injury. Interact. Cardiovasc. Thorac. Surg. 23, 800–805 (2016).
Damman, K. et al. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J. Am. Coll. Cardiol. 53, 582–588 (2009).
Marik, P. E., Baram, M. & Vahid, B. Does central venous pressure predict fluid responsiveness? A systematic review of the literature and the tale of seven mares. Chest 134, 172–178 (2008).
Castrop, H. Mediators of tubuloglomerular feedback regulation of glomerular filtration: ATP and adenosine. Acta Physiol. 189, 3–14 (2007).
Bell, T. D. & Welch, W. J. Regulation of renal arteriolar tone by adenosine: novel role for type 2 receptors. Kidney Int. 75, 769–771 (2009).
Agarwal, R. Prevalence, determinants and prognosis of pulmonary hypertension among hemodialysis patients. Nephrol. Dial. Transplant. 27, 3908–3914 (2012).
Abedini, M., Sadeghi, M., Naini, A. E., Atapour, A. & Golshahi, J. Pulmonary hypertension among patients on dialysis and kidney transplant recipients. Ren. Fail. 35, 560–565 (2013).
Ramasubbu, K., Deswal, A., Herdejurgen, C., Aguilar, D. & Frost, A. E. A prospective echocardiographic evaluation of pulmonary hypertension in chronic hemodialysis patients in the United States: prevalence and clinical significance. Int. J. Gen. Med. 3, 279–286 (2010).
Issa, N. et al. Pulmonary hypertension is associated with reduced patient survival after kidney transplantation. Transplantation 86, 1384–1388 (2008).
de Albuquerque Suassuna, P. G., Sanders-Pinheiro, H. & de Paula, R. B. Uremic cardiomyopathy: a new piece in the chronic kidney disease-mineral and bone disorder puzzle. Front. Med. 5, 206 (2018).
Ma, Z. et al. β-Arrestin-mediated angiotensin II type 1 receptor activation promotes pulmonary vascular remodeling in pulmonary hypertension. JACC Basic. Transl. Sci. 6, 854–869 (2021).
de Man, F. S. et al. Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 186, 780–789 (2012).
Houston, B. A., Brittain, E. L. & Tedford, R. J. Right ventricular failure. N. Engl. J. Med. 388, 1111–1125 (2023).
Wu, D. & Birukov, K. Endothelial cell mechano-metabolomic coupling to disease states in the lung microvasculature. Front. Bioeng. Biotechnol. 7, 172 (2019).
Silva, P. L. et al. Hypervolemia induces and potentiates lung damage after recruitment maneuver in a model of sepsis-induced acute lung injury. Crit. Care 14, R114 (2010).
Tonelli, A. R., Plana, J. C., Heresi, G. A. & Dweik, R. A. Prevalence and prognostic value of left ventricular diastolic dysfunction in idiopathic and heritable pulmonary arterial hypertension. Chest 141, 1457–1465 (2012).
Stern, A. B. & Klemmer, P. J. High-output heart failure secondary to arteriovenous fistula. Hemodial. Int. 15, 104–107 (2011).
Reddy, Y. N. V., Melenovsky, V., Redfield, M. M., Nishimura, R. A. & Borlaug, B. A. High-output heart failure: a 15-year experience. J. Am. Coll. Cardiol. 68, 473–482 (2016).
Holman, E. Abnormal arteriovenous communications. Great variability of effects with particular reference to delayed development of cardiac failure. Circulation 32, 1001–1009 (1965).
Warren, J. V., Elkin, D. C. & Nickerson, J. L. The blood volume in patients with arteriovenous fistulas. J. Clin. Invest. 30, 220–226 (1951).
Rao, N. N., Dundon, B. K., Worthley, M. I. & Faull, R. J. The impact of arteriovenous fistulae for hemodialysis on the cardiovascular system. Semin. Dial. 29, 214–221 (2016).
MacRae, J. M., Pandeya, S., Humen, D. P., Krivitski, N. & Lindsay, R. M. Arteriovenous fistula-associated high-output cardiac failure: a review of mechanisms. Am. J. Kidney Dis. 43, 17 (2004).
Ori, Y. et al. The contribution of an arteriovenous access for hemodialysis to left ventricular hypertrophy. Am. J. Kidney Dis. 40, 745–752 (2002).
Malik, J. et al. Hemodialysis vascular access affects heart function and outcomes: tips for choosing the right access for the individual patient. J. Vasc. Access. 22, 32–41 (2021).
Iwashima, Y. et al. Effects of the creation of arteriovenous fistula for hemodialysis on cardiac function and natriuretic peptide levels in CRF. Am. J. Kidney Dis. 40, 974–982 (2002).
Reddy, Y. N. V. et al. Long-term cardiovascular changes following creation of arteriovenous fistula in patients with end stage renal disease. Eur. Heart J. 38, 1913–1923 (2017).
Unger, P., Wissing, K. M., de Pauw, L., Neubauer, J. & van de Borne, P. Reduction of left ventricular diameter and mass after surgical arteriovenous fistula closure in renal transplant recipients. Transplantation 74, 73–79 (2002).
van Duijnhoven, E. C., Cheriex, E. C., Tordoir, J. H., Kooman, J. P. & van Hooff, J. P. Effect of closure of the arteriovenous fistula on left ventricular dimensions in renal transplant patients. Nephrol. Dial. Transplant. 16, 368–372 (2001).
Gumus, F. & Saricaoglu, M. C. Assessment of right heart functions in the patients with arteriovenous fistula for hemodialysis access: right ventricular free wall strain and tricuspid regurgitation jet velocity as the predictors of right heart failure. Vascular 28, 96–103 (2020).
Manzur-Pineda, K. et al. Echocardiographic changes after arteriovenous fistula creation in hemodialysis patients. Clin. Nephrol. 98, 229–238 (2022).
Hetz, P. et al. Prophylactic ligature of AV fistula prevents high output heart failure after kidney transplantation. Am. J. Nephrol. 51, 511–519 (2020).
Stoumpos, S. & Mark, P. B. Should we ligate arteriovenous fistulas in asymptomatic patients after kidney transplantation? Circulation 139, 2819–2821 (2019).
Rodriguez-Espinosa, D. et al. Multimodal strategies for the diagnosis and management of refractory congestion. an integrated cardiorenal approach. Front. Physiol. 13, 913580 (2022).
Southgate, L., Machado, R. D., Graf, S. & Morrell, N. W. Molecular genetic framework underlying pulmonary arterial hypertension. Nat. Rev. Cardiol. 17, 85–95 (2020).
Hassoun, P. M. Pulmonary arterial hypertension. N. Engl. J. Med. 385, 2361–2376 (2021).
Kaiser, R., Seiler, S., Held, M., Bals, R. & Wilkens, H. Prognostic impact of renal function in precapillary pulmonary hypertension. J. Intern. Med. 275, 116–126 (2014).
D’Apolito, M. et al. Urea-induced ROS cause endothelial dysfunction in chronic renal failure. Atherosclerosis 239, 393–400 (2015).
Giaid, A. et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 328, 1732–1739 (1993).
Chester, A. H. & Yacoub, M. H. The role of endothelin-1 in pulmonary arterial hypertension. Glob. Cardiol. Sci. Pract. 2014, 62–78 (2014).
Shao, D., Park, J. E. S. & Wort, S. J. The role of endothelin-1 in the pathogenesis of pulmonary arterial hypertension. Pharmacol. Res. 63, 504–511 (2011).
Din, S., Sarathchandra, P., Yacoub, M. H. & Chester, A. H. Interaction between bone morphogenetic proteins and endothelin-1 in human pulmonary artery smooth muscle. Vasc. Pharmacol. 51, 344–349 (2009).
Ern Yeoh, S. et al. Endothelin-1, outcomes in patients with heart failure and reduced ejection fraction, and effects of dapagliflozin: findings from DAPA-HF. Circulation 147, 1670–1683 (2023).
Rossi, G. P., Belloni, A. S., Nussdorfer, G. G. & Pessina, A. C. Endothelin-1 and the adrenal gland. J. Cardiovasc. Pharmacol. 35, 17 (2000).
Miller, W. L., Redfield, M. M. & Burnett, J. C. J. Integrated cardiac, renal, and endocrine actions of endothelin. J. Clin. Invest. 83, 317–320 (1989).
Cao, L. Q. & Banks, R. O. Cardiorenal actions of endothelin, Part II: effects of cyclooxygenase inhibitors. Life Sci. 46, 585–590 (1990).
Boehm, M. et al. Eplerenone attenuates pathological pulmonary vascular rather than right ventricular remodeling in pulmonary arterial hypertension. BMC Pulm. Med. 18, 41–4 (2018).
Lariviere, R. et al. Increased immunoreactive endothelin-1 levels in blood vessels and glomeruli of rats with reduced renal mass. Kidney Blood Press. Res. 20, 372–380 (1997).
Zager, R. A., Johnson, A. C. M., Andress, D. & Becker, K. Progressive endothelin-1 gene activation initiates chronic/end-stage renal disease following experimental ischemic/reperfusion injury. Kidney Int. 84, 703–712 (2013).
Raina, R. et al. Relationship of urinary endothelin-1 with estimated glomerular filtration rate in autosomal dominant polycystic kidney disease: a pilot cross-sectional analysis. BMC Nephrol. 17, 22–28 (2016).
Long, L. et al. Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension. Nat. Med. 21, 777–785 (2015).
Yeh, C. H., Chang, C. K., Cheng, M. F., Lin, H. J. & Cheng, J. T. Decrease of bone morphogenetic protein-7 (BMP-7) and its type II receptor (BMP-RII) in kidney of type 1-like diabetic rats. Horm. Metab. Res. 41, 605–611 (2009).
Jiang, Q. et al. Dysregulation of BMP9/BMPR2/SMAD signalling pathway contributes to pulmonary fibrosis and pulmonary hypertension induced by bleomycin in rats. Br. J. Pharmacol. 178, 203–216 (2021).
Star, G. P., Giovinazzo, M. & Langleben, D. Bone morphogenic protein-9 stimulates endothelin-1 release from human pulmonary microvascular endothelial cells: a potential mechanism for elevated ET-1 levels in pulmonary arterial hypertension. Microvasc. Res. 80, 349–354 (2010).
Park, J. E. S. et al. BMP-9 induced endothelial cell tubule formation and inhibition of migration involves Smad1 driven endothelin-1 production. PLoS One 7, e30075 (2012).
Tu, L. et al. Selective BMP-9 inhibition partially protects against experimental pulmonary hypertension. Circ. Res. 124, 846–855 (2019).
Zhu, D. et al. BMP-9 regulates the osteoblastic differentiation and calcification of vascular smooth muscle cells through an ALK1 mediated pathway. J. Cell. Mol. Med. 19, 165–174 (2015).
Zeisberg, M. et al. BMP-7 counteracts TGF-β1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat. Med. 9, 964–968 (2003).
Wang, S., Lapage, J. & Hirschberg, R. Loss of tubular bone morphogenetic protein-7 in diabetic nephropathy. J. Am. Soc. Nephrol. 12, 2392–2399 (2001).
Kong, L. et al. Sulforaphane ameliorates diabetes-induced renal fibrosis through epigenetic up-regulation of BMP-7. Diabetes Metab. J. 45, 909–920 (2021).
Zeisberg, M. et al. Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models. Am. J. Physiol. Renal Physiol. 285, 1060 (2003).
Mitu, G. & Hirschberg, R. Bone morphogenetic protein-7 (BMP7) in chronic kidney disease. Front. Biosci. 13, 4726–4739 (2008).
Morrissey, J. et al. Bone morphogenetic protein-7 improves renal fibrosis and accelerates the return of renal function. J. Am. Soc. Nephrol. 13, 14 (2002).
Schrankl, J. et al. Localization of angiotensin II type 1 receptor gene expression in rodent and human kidneys. Am. J. Physiol. Renal Physiol. 320, F644–F653 (2021).
Rianto, F., Hoang, T., Revoori, R. & Sparks, M. A. Angiotensin receptors in the kidney and vasculature in hypertension and kidney disease. Mol. Cell. Endocrinol. 529, 111259 (2021).
Betjes, M. G. H., Sablik, K. A., Litjens, N. H. R., Otten, H. G. & de Weerd, A. E. ARHGDIB and AT1R autoantibodies are differentially related to the development and presence of chronic antibody-mediated rejection and fibrosis in kidney allografts. Hum. Immunol. 82, 89–96 (2021).
Xu, Z. et al. Gentiopicroside ameliorates diabetic renal tubulointerstitial fibrosis via inhibiting the AT1R/CK2/NF-κB pathway. Front. Pharmacol. 13, 848915 (2022).
Block, G. A. et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J. Am. Soc. Nephrol. 15, 2208–2218 (2004).
Tentori, F. et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am. J. Kidney Dis. 52, 519–530 (2008).
Kestenbaum, B. et al. Survival following parathyroidectomy among United States dialysis patients. Kidney Int. 66, 2010–2016 (2004).
Komaba, H. et al. Parathyroidectomy and survival among Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int. 88, 350–359 (2015).
Ivarsson, K. M. et al. The effect of parathyroidectomy on patient survival in secondary hyperparathyroidism. Nephrol. Dial. Transplant. 30, 2027–2033 (2015).
Ulrich, S. et al. Bone mineral density and secondary hyperparathyroidism in pulmonary hypertension. Open. Respir. Med. J. 3, 53–60 (2009).
Genctoy, G., Arikan, S. & Gedik, O. Secondary hyperparathyroidism is associated with pulmonary hypertension in older patients with chronic kidney disease and proteinuria. Int. Urol. Nephrol. 47, 353–358 (2015).
Amin, M., Fawzy, A., Hamid, M. A. & Elhendy, A. Pulmonary hypertension in patients with chronic renal failure: role of parathyroid hormone and pulmonary artery calcifications. Chest 124, 2093–2097 (2003).
Acarturk, G. et al. The relationship between arteriovenous fistula blood flow rate and pulmonary artery pressure in hemodialysis patients. Int. Urol. Nephrol. 40, 509–513 (2008).
Akmal, M., Barndt, R. R., Ansari, A. N., Mohler, J. G. & Massry, S. G. Excess PTH in CRF induces pulmonary calcification, pulmonary hypertension and right ventricular hypertrophy. Kidney Int. 47, 158–163 (1995).
Komaba, H. & Fukagawa, M. The role of FGF23 in CKD — with or without Klotho. Nat. Rev. Nephrol. 8, 484–490 (2012).
Miri, M., Ahmadi, M. & Hatami, M. Correlation between fibroblast growth factor-23 and pulmonary arterial hypertension in hemodialysis patients. Iran. J. Kidney Dis. 15, 300–305 (2021).
Widmann, L. et al. Fibroblast growth factor 23 as a biomarker of right ventricular dysfunction in pulmonary hypertension. Clin. Res. Cardiol. 112, 1382–1393 (2023).
Hu, M. C. et al. Klotho deficiency causes vascular calcification in chronic kidney disease. J. Am. Soc. Nephrol. 22, 124–136 (2011).
Kurosu, H. et al. Suppression of aging in mice by the hormone Klotho. Science 309, 1829–1833 (2005).
Mitani, H. et al. In vivo klotho gene transfer ameliorates angiotensin II-induced renal damage. Hypertension 39, 838–843 (2002).
Varshney, R., Ali, Q., Wu, C. & Sun, Z. Monocrotaline-induced pulmonary hypertension involves downregulation of antiaging protein Klotho and eNOS activity. Hypertension 68, 1255–1263 (2016).
Batlahally, S. et al. Soluble Klotho, a biomarker and therapeutic strategy to reduce bronchopulmonary dysplasia and pulmonary hypertension in preterm infants. Sci. Rep. 10, 12368 (2020).
Chadban, S. J. et al. KDIGO clinical practice guideline on the evaluation and management of candidates for kidney transplantation. Transplantation 104, S11–S103 (2020).
Abramowicz, D. et al. European renal best practice guideline on kidney donor and recipient evaluation and perioperative care. Nephrol. Dial. Transplant. 30, 1790–1797 (2015).
Knoll, G. et al. Canadian Society of Transplantation: consensus guidelines on eligibility for kidney transplantation. CMAJ 173, 1 (2005).
Frost, A. E. et al. The echocardiographic course of pretransplant pulmonary hypertension following kidney transplantation and associated outcomes. Pulm. Circ. 12, e12030 (2022).
Hoeper, M. M. et al. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N. Engl. J. Med. 388, 1478–1490 (2023).
Stickel, S., Gin-Sing, W., Wagenaar, M. & Gibbs, J. S. R. The practical management of fluid retention in adults with right heart failure due to pulmonary arterial hypertension. Eur. Heart J. Suppl. 21, K46–K53 (2019).
Webb, D. J., Vachiery, J., Hwang, L. & Maurey, J. O. Sildenafil improves renal function in patients with pulmonary arterial hypertension. Br. J. Clin. Pharmacol. 80, 235–241 (2015).
Heerspink, H. J. L. et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet 393, 1937–1947 (2019).
Krowka, M. J. et al. International Liver Transplant Society practice guidelines: diagnosis and management of hepatopulmonary syndrome and portopulmonary hypertension. Transplantation 100, 1440–1452 (2016).
Nevola, R. et al. Cardiorenal impact of SGLT-2 inhibitors: a conceptual revolution in the management of type 2 diabetes, heart failure and chronic kidney disease. Rev. Cardiovasc. Med. 23, 106 (2022).
Nassif, M. E. et al. Empagliflozin effects on pulmonary artery pressure in patients with heart failure: results from the EMBRACE-HF trial. Circulation 143, 1673–1686 (2021).
Pellicori, P. et al. Ultrasound imaging of congestion in heart failure: examinations beyond the heart. Eur. J. Heart Fail. 23, 703–712 (2021).
- The Renal Warrior Project. Join Now
- Source: https://www.nature.com/articles/s41581-024-00857-7